Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

Mise à jour : Il y a 5 ans
Référence : NCT01275209

Femme et Homme

Extrait

This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.


Critère d'inclusion

  • Follicular lymphoma


Liens